ESTRELLA IMMUNOPHARMA, INC. Derivative Liability
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Derivative Liability of $687.22 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2026-08-13
- 2026-06-30: Derivative Liability $687.22K.
- 2026-03-31: Derivative Liability $465.13K.
- 2025-12-31: Derivative Liability $356.50K.
- 2025-09-30: Derivative Liability $385.36K.
| Period end | Derivative Liability | Derivative Liability as first filed |
|---|---|---|
| 2026-06-30 | $687.22K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $465.13K 10-Q · filed 2026-05-18 | |
| 2025-12-31 | $356.50K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $385.36K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $187.94K 10-Q · filed 2025-08-12 | |
| 2024-12-31 | $318.32K 10-K · filed 2026-03-18 | $187.94K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |